Literature DB >> 6581852

Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.

R S Schwartz, F R Mackintosh, S L Schrier, P L Greenberg.   

Abstract

The clinical courses of 54 consecutive adult patients with acute myelogenous leukemia (AML) who underwent 67 courses of intensive remission induction therapy were analyzed to assess factors associated with development of serious fungal and bacterial infections. Fever developed in 65 of 67 remission induction attempts and was due to bacterial, bacterial-fungal, and fungal etiologies in 49%, 14%, and 9% of cases, respectively. No etiology of fever was found in 28% of cases. Bacteremia occurred in 54% of remission induction attempts. Invasive fungal disease (IFD) occurred in 22% of cases with an overall mortality of 60%, including 45% of the patients who died during treatment. Using multivariate logistic regression analysis, a mathematical model was constructed which correlated with the risk of IFD. Major factors associated with patients who ultimately develop IFD included the duration of chemotherapy, the number of sites colonized with fungi and the number of fungal species isolated on certain surveillance cultures, particularly Aspergillus species. These studies define characteristics of patients at high risk for development of IFD for whom early initiation of empiric antifungal therapy is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6581852     DOI: 10.1002/1097-0142(19840201)53:3<411::aid-cncr2820530308>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

2.  Development of a chromosomal DNA probe for the laboratory diagnosis of aspergillosis.

Authors:  M A Gabal
Journal:  Mycopathologia       Date:  1989-05       Impact factor: 2.574

3.  Risk factors for candidemia in cancer patients: a case-control study.

Authors:  A Karabinis; C Hill; B Leclercq; C Tancrède; D Baume; A Andremont
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

4.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  Management of pulmonary aspergillosis in AIDS: an emerging clinical problem.

Authors:  J J Keating; T Rogers; M Petrou; J D Cartledge; D Woodrow; M Nelson; D A Hawkins; B G Gazzard
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

6.  Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.

Authors:  S Takakura; N Fujihara; T Saito; T Kudo; Y Iinuma; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

7.  Pseudoepidemic of aspergillosis after development of pulmonary infiltrates in a group of bone marrow transplant patients.

Authors:  J J Weems; A Andremont; B J Davis; C H Tancrede; M Guiguet; A A Padhye; F Squinazi; W J Martone
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

8.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

9.  Model of recurrent pulmonary aspergillosis in rats.

Authors:  Y Niki; E M Bernard; F F Edwards; H J Schmitt; B Yu; D Armstrong
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

10.  Invasive aspergillosis complicating induction chemotherapy of childhood leukaemia.

Authors:  T Bömelburg; N Roos; H J von Lengerke; J Ritter
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.